McKesson Corporation $MCK Shares Bought by DSG Capital Advisors LLC

DSG Capital Advisors LLC increased its holdings in McKesson Corporation (NYSE:MCK) by 20.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,134 shares of the company’s stock after acquiring an additional 690 shares during the quarter. DSG Capital Advisors LLC’s holdings in McKesson were worth $3,530,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Secure Asset Management LLC grew its holdings in shares of McKesson by 484.8% during the 2nd quarter. Secure Asset Management LLC now owns 2,123 shares of the company’s stock worth $1,604,000 after acquiring an additional 1,760 shares during the period. BayBridge Capital Group LLC lifted its stake in shares of McKesson by 268.0% in the 2nd quarter. BayBridge Capital Group LLC now owns 1,943 shares of the company’s stock valued at $1,468,000 after purchasing an additional 1,415 shares during the period. Royal London Asset Management Ltd. lifted its stake in shares of McKesson by 1.1% in the 2nd quarter. Royal London Asset Management Ltd. now owns 112,241 shares of the company’s stock valued at $84,809,000 after purchasing an additional 1,216 shares during the period. Benchmark Investment Advisors LLC bought a new stake in shares of McKesson during the second quarter valued at approximately $441,000. Finally, Summit Global Investments bought a new stake in shares of McKesson during the second quarter valued at approximately $1,159,000. Institutional investors own 85.07% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Mizuho increased their price objective on McKesson from $905.00 to $1,020.00 and gave the stock a “neutral” rating in a report on Tuesday, October 20th. Bank of America increased their price target on shares of McKesson from $950.00 to $1,050.00 in a research note on Thursday, August 6th. Leerink Partners lifted their price target on shares of McKesson from $1,070.00 to $1,200.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. JPMorgan Chase & Co. boosted their price objective on shares of McKesson from $1,042.00 to $1,255.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Wells Fargo & Company upped their price objective on shares of McKesson from $812.00 to $933.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 11th. Fifteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, McKesson presently has an average rating of “Moderate Buy” and a consensus target price of $1,040.29.

McKesson Trading Up 2.3%

Shares of NYSE:MCK opened at $1,083.95 on Wednesday. The stock has a fifty day simple moving average of $945.38 and a two-hundred day simple moving average of $870.63. The stock has a market capitalization of $125.15 billion, a price-to-earnings ratio of 24.84, a PEG ratio of 1.79 and a beta of 0.27. McKesson Corporation has a 12-month low of $723.68 and a 12-month high of $1,121.50.

McKesson (NYSE:MCK) last released its earnings results on Wednesday, November 4th. The company reported $11.68 EPS for the quarter, topping analysts’ consensus estimates of $10.72 by $0.96. McKesson had a negative return on equity of 202.94% and a net margin of 1.12%. The firm had revenue of $110.96 billion for the quarter, compared to analysts’ expectations of $109.90 billion. During the same period in the prior year, the firm posted $9.86 earnings per share. The company’s quarterly revenue was up 7.5% on a year-over-year basis. As a group, equities research analysts predict that McKesson Corporation will post 46.16 EPS for the current year.

McKesson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Tuesday, December 1st will be paid a $0.94 dividend. The ex-dividend date is Tuesday, December 1st. This represents a $3.76 dividend on an annualized basis and a yield of 0.3%. McKesson’s payout ratio is presently 9.67%.

Insider Transactions at McKesson

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 111 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $891.45, for a total transaction of $98,950.95. Following the completion of the sale, the chief accounting officer directly owned 521 shares in the company, valued at approximately $464,445.45. This trade represents a 17.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Francisco Fraga sold 800 shares of McKesson stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $995.80, for a total transaction of $796,640.00. Following the completion of the transaction, the executive vice president directly owned 5,423 shares of the company’s stock, valued at $5,400,223.40. This trade represents a 12.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 2,161 shares of company stock worth $2,242,515. 0.06% of the stock is currently owned by company insiders.

McKesson Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers. The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care. Founded in 1833, McKesson serves customers primarily in the United States and Canada.